HOUSTON, June 27, 2014 /PRNewswire/ -- The Burzynski
Research Institute, Inc. (BRI) announced today that it will
present data on two of the Company's clinical-stage product
candidates, Antineoplaston A10 injections (Atengenal®)
and Antineoplaston AS2-1 injections (Astugenal®), at the
16th International Symposium on Pediatric Neuro-Oncology
held in Singapore from
June 28, 2014 to July 2, 2014. Abstracts and presentations
are now available to the public in an online supplement in the
journal, Neuro-Oncology (Neuro Oncol 2014 June; 16(Suppl 1):
i1-i157). The abstract numbers are CT-004, HG-017, and
MB-039. The journal's TOC web address is
http://neuro-oncology.oxfordjournals.org/content/16/suppl_1.toc.
Highlights from Abstract CT-004
The abstract title is "A phase II study of Antineoplastons A10 and
AS2-1 in children with recurrent, refractory or progressive primary
brain tumors based on Protocol BT-22." Primary malignant
brain tumors are the leading cause of cancer-related death in
children. This single arm two-stage phase II study evaluated
the efficacy and safety of combination of Antineoplastons A10 and
AS2-1 (ANP) in children who developed progression of primary brain
tumors during standard treatment. A total of 30 children who
met the eligibility criteria were treated according to Protocol
BT-22 at the Burzynski Clinic (BC). There were 8 cases of
glioblastoma (GBM), 11 cases of diffuse intrinsic pontine glioma
(DIPG), 6 cases of anaplastic astrocytoma (AA), 2 cases of
primitive neuroectodermal tumors (sPNET) and 1 case each of
atypical teratoid rhabdoid tumor (ATR), disseminated pilocytic
astrocytoma, and medulloblastoma (PNET). Five patients (17%)
obtained complete and partial responses; four patients were
diagnosed with recurrent DIPG, and one with recurrent AA. The
longest survivor is a patient diagnosed with DIPG and disseminated
gliosarcoma who remains alive more than 14 years from the treatment
start. A small group of patients reported serious toxicity
including hypernatremia, somnolence, and hypokalemia.
It is concluded that antineoplastons showed efficacy within an
acceptable profile in this group of patients with recurrent,
refractory or progressive primary brain tumors.
Titles of Abstracts HG-017 and MB-039
Abstract HG-017: A long-term survival (over 20 years) and
pathologically confirmed complete response in pediatric anaplastic
astrocytoma: a case report.
Abstract MB-039: Long-term survival (over 20 years), complete
response and normal childhood development in medulloblastoma (PNET)
without recurrence: a case report.
The abstracts are scheduled for presentation in the poster
session on June 30, 2014 from
6 PM to 8 PM.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a
biopharmaceutical company committed to developing treatment for
cancer based on genomic and epigenetic principles. Research
and development efforts are focused on basic research and phase III
clinical trials.
Forward-looking statements in this release are made pursuant
to the safe harbor provisions of the federal securities laws.
Information contained in forward-looking statements is based on
current expectations and is subject to change, and future events
may differ materially from those discussed herein due to a number
of factors, including, but not limited to, risks and uncertainties
related to the ability to use Antineoplastons A10 and AS2-1.
Burzynski Research Institute, Inc. does not undertake to update any
such forward-looking statements or to publicly announce
developments or events relating to the matters described
herein.
SOURCE Burzynski Research Institute, Inc.